Found: 40
Select item for more details and to access through your institution.
Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer.
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
Erratum to: Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer.
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance)
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
Patupilone in patients with pretreated metastatic/locally recurrent colorectal cancer: results of the Phase II CINATRA trial.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1339, doi. 10.1007/s10637-013-9990-3
- By:
- Publication type:
- Article
Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer-CRAFT study.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1321, doi. 10.1007/s10637-013-9982-3
- By:
- Publication type:
- Article
A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1300, doi. 10.1007/s10637-013-9973-4
- By:
- Publication type:
- Article
Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: Results of a Phase II trial.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1330, doi. 10.1007/s10637-013-9985-0
- By:
- Publication type:
- Article
Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1201, doi. 10.1007/s10637-013-0004-2
- By:
- Publication type:
- Article
Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1275, doi. 10.1007/s10637-013-9941-z
- By:
- Publication type:
- Article
Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1192, doi. 10.1007/s10637-013-0003-3
- By:
- Publication type:
- Article
Role of IL-8 induced angiogenesis in uveal melanoma.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1107, doi. 10.1007/s10637-013-0005-1
- By:
- Publication type:
- Article
Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1251, doi. 10.1007/s10637-013-9946-7
- By:
- Publication type:
- Article
Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1169, doi. 10.1007/s10637-013-9968-1
- By:
- Publication type:
- Article
The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1375, doi. 10.1007/s10637-013-9967-2
- By:
- Publication type:
- Article
Novel bourgeonal fragrance conjugates for the detection of prostate cancer.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1151, doi. 10.1007/s10637-013-9943-x
- By:
- Publication type:
- Article
A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1182, doi. 10.1007/s10637-013-0001-5
- By:
- Publication type:
- Article
Bcl-2 antagonists: a proof of concept for CLL therapy.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1384, doi. 10.1007/s10637-013-0002-4
- By:
- Publication type:
- Article
A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1294, doi. 10.1007/s10637-013-9972-5
- By:
- Publication type:
- Article
Erratum to: Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer.
- Published in:
- 2013
- By:
- Publication type:
- Correction Notice
A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1257, doi. 10.1007/s10637-013-9947-6
- By:
- Publication type:
- Article
Bronchoscopic findings for bevacizumab-related pulmonary hemorrhage in advanced non-small cell lung cancer.
- Published in:
- 2013
- By:
- Publication type:
- Report
Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1236, doi. 10.1007/s10637-013-9942-y
- By:
- Publication type:
- Article
Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1283, doi. 10.1007/s10637-013-9962-7
- By:
- Publication type:
- Article
A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1307, doi. 10.1007/s10637-013-9976-1
- By:
- Publication type:
- Article
Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors.
- Published in:
- 2013
- By:
- Publication type:
- Report
Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1136, doi. 10.1007/s10637-013-9928-9
- By:
- Publication type:
- Article
Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1158, doi. 10.1007/s10637-013-9959-2
- By:
- Publication type:
- Article
In silico analysis of the amido phosphoribosyltransferase inhibition by PY873, PY899 and a derivative of isophthalic acid.
- Published in:
- 2013
- By:
- Publication type:
- Report
Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1345, doi. 10.1007/s10637-013-9991-2
- By:
- Publication type:
- Article
Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1125, doi. 10.1007/s10637-013-9923-1
- By:
- Publication type:
- Article
A Phase I Study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1244, doi. 10.1007/s10637-013-9945-8
- By:
- Publication type:
- Article
An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1228, doi. 10.1007/s10637-013-9938-7
- By:
- Publication type:
- Article
Digalloylresveratrol, a novel resveratrol analog inhibits the growth of human pancreatic cancer cells.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1115, doi. 10.1007/s10637-013-0009-x
- By:
- Publication type:
- Article
Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1265, doi. 10.1007/s10637-012-9910-y
- By:
- Publication type:
- Article
Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1142, doi. 10.1007/s10637-013-9932-0
- By:
- Publication type:
- Article
Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1207, doi. 10.1007/s10637-013-9933-z
- By:
- Publication type:
- Article
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1311, doi. 10.1007/s10637-013-9978-z
- By:
- Publication type:
- Article
Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1097, doi. 10.1007/s10637-012-9915-6
- By:
- Publication type:
- Article
Erratum to: Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI.
- Published in:
- 2013
- By:
- Publication type:
- Correction Notice
Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1217, doi. 10.1007/s10637-013-9937-8
- By:
- Publication type:
- Article